Skip to main content
. 2015 Oct 12;10(3):382–390. doi: 10.5009/gnl14319

Fig. 7.

Fig. 7

The expression of vasoactive intestinal peptide (VIP) in the colon as evaluated by immunohistochemistry (×200). (A) Control subjects; (B) irritable bowel syndrome-diarrhea (IBS-D) patients; (C) irritable bowel syndrome-constipation (IBS-C) patients. (D) An increase in VIP was found in IBS-D patients compared to control subjects, and there was a significant difference between the IBS-D and IBS-C groups. *p<0.05 compared with control subjects; p<0.05 compared with IBS-C patients.